BNP Paribas Financial Markets
ACUR

BNP Paribas Financial Markets’s Acura Pharmaceuticals ACUR Stock Holding History

BNP Paribas Financial Markets’s Portfolio ACUR Stock Details ACUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-14
Closed -$78 – 4417
2014
Q2 		$78 Hold
14
– – ﹤0.01% 3771
2014
Q1 		$99 Hold
14
– – ﹤0.01% 3299
2013
Q4 		$120 Buy
+14
New +$118 ﹤0.01% 4049

Other funds holding ACUR

EWM
Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return

BNP Paribas Financial Markets's ACUR Position: Q3 2014 in Review

BNP Paribas Financial Markets sold out of Acura Pharmaceuticals (ACUR) in Q3 2014, closing a stake of 14 shares — an estimated $78 sold.

BNP Paribas Financial Markets first reported a position in ACUR in Q4 2013 and held it in 3 quarters. The position peaked at $120 in Q4 2013. 28 funds tracked by Wall St. Rank hold ACUR as of Q3 2014.

  • BNP Paribas Financial Markets reported no remaining Acura Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 14 Acura Pharmaceuticals shares in Q3 2014, an estimated $78.
  • BNP Paribas Financial Markets first reported a position in Acura Pharmaceuticals in Q4 2013 and held it in 3 quarters.
  • BNP Paribas Financial Markets's Acura Pharmaceuticals position peaked at $120 in Q4 2013.
  • 28 funds tracked by Wall St. Rank held Acura Pharmaceuticals as of Q3 2014.

Based on BNP Paribas Financial Markets's 13F filing for Q3 2014, filed 12 Nov 2014.